Peter Rhode's most recent trade in HCW Biologics Inc was a trade of 14,000 Common Stock done at an average price of $0.1 . Disclosure was reported to the exchange on Dec. 11, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| HCW Biologics Inc | Peter Rhode | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.14 per share. | 11 Dec 2023 | 14,000 | 77,500 | - | 0.1 | 1,960 | Common Stock |
| HCW Biologics Inc | Peter Rhode | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2023 | 14,000 | 22,427 | - | - | Stock Option (Right to Buy) | |
| HCW Biologics Inc | Peter Rhode | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 1,714 | 6,857 | - | - | Stock Option Grant (Right to Buy) | |
| HCW Biologics Inc | Peter Rhode | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.21 per share. | 14 Jan 2022 | 1,714 | 48,499 | - | 0.2 | 360 | Common Stock |
| HCW Biologics Inc | Peter Rhode | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 1 | 48,500 | - | 0 | Common Stock | |
| HCW Biologics Inc | Peter Rhode | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 1 | 51,427 | - | - | Stock Option Grant (Right to Buy) | |
| HCW Biologics Inc | Peter Rhode | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) |